Impact assessment

Regulations under the Health Act 2009: Control of Entry and Exit in the NHS Pharmaceutical Market: Impact Assessment

Impact assessment (IA 5035) on the control of entry and exit in the NHS pharmaceutical market

This was published under the 2010 to 2015 Conservative and Liberal Democrat coalition government

Documents

Control of Entry and Exit in the NHS Pharmaceutical Market: Impact Assessment

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dh.gsi.gov.uk . Please tell us what format you need. It will help us if you say what assistive technology you use.

Equality Analysis

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dh.gsi.gov.uk . Please tell us what format you need. It will help us if you say what assistive technology you use.

RPC Opinion

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dh.gsi.gov.uk . Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

To ensure a proportionate regulatory regime which encourages the supply of NHS pharmaceutical services without excessive provision in areas already adequately meeting demand, to ensure the benefits of new entry outweigh costs and to align provision more transparently with local needs.

Published 24 July 2012